|
|
|
|
| LEADER |
00000cam a22000007i 4500 |
| 001 |
on1374069948 |
| 003 |
OCoLC |
| 005 |
20240909213021.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
230327s2023 sz a o 001 0 eng d |
| 040 |
|
|
|a GW5XE
|b eng
|e rda
|e pn
|c GW5XE
|d EBLCP
|d YDX
|d UKAHL
|d OCLCF
|d YDX
|d OCLCQ
|d OCLCO
|d N$T
|
| 019 |
|
|
|a 1373607588
|a 1373987997
|
| 020 |
|
|
|a 3031210549
|q electronic book
|
| 020 |
|
|
|a 9783031210549
|q (electronic bk.)
|
| 020 |
|
|
|z 3031210530
|
| 020 |
|
|
|z 9783031210532
|
| 024 |
7 |
|
|a 10.1007/978-3-031-21054-9
|2 doi
|
| 035 |
|
|
|a (OCoLC)1374069948
|z (OCoLC)1373607588
|z (OCoLC)1373987997
|
| 050 |
|
4 |
|a RM315
|b .D78 2023
|
| 072 |
|
7 |
|a PSAN
|2 bicssc
|
| 072 |
|
7 |
|a MED057000
|2 bisacsh
|
| 072 |
|
7 |
|a PSAN
|2 thema
|
| 049 |
|
|
|a HCDD
|
| 245 |
0 |
0 |
|a Drug development in psychiatry /
|c Matthew Macaluso, Sheldon H. Preskorn, Richard C. Shelton, editors.
|
| 264 |
|
1 |
|a Cham, Switzerland :
|b Springer,
|c [2023]
|
| 300 |
|
|
|a 1 online resource (519 pages) :
|b illustrations (black and white, and colour).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in neurobiology ;
|v 30
|
| 505 |
0 |
|
|a Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development -- The History of Drug Development in Psychiatry: A Lesson in Serendipity -- The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric Disorders -- Discovery and Development of Monoamine Transporter Ligands -- Drug Development for New Psychiatric Drug Therapies -- Post-Approval Research in Drug Development: Priorities and Practices -- Discovery of new transmitter systems and hence new drug targets -- Reverse engineering drugs -- Back to the Future of Neuropsychopharmacology -- Targeted Treatments for Fragile X Syndrome -- The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders Diseases -- Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics -- The role of fMRI in drug development: an update -- Monoamine Oxidase B (MAO-B): A Target for Rational Drug Development in Schizophrenia Using PET Imaging as an Example -- Genomics in Treatment Development -- Increased Inflammation and Treatment of Depression: from Resistance to Reuse, Repurposing and Redesign -- Experimental medicine approaches in early phase CNS drug development.
|
| 520 |
|
|
|a This new book reviews clinical trial methodology as it pertains to drug development in psychiatry. The authors will describe the process of drug development in psychiatry from discovery through marketing with the help of clinically relevant examples. The history of drug development in psychiatry is explored dating back to the era of serendipitous discovery and culminating in an era of new and highly focused targets. The book will delineate how drug development in psychiatry has changed and adapted with the discovery of drugs with novel mechanisms of action. Drug Development in Psychiatry elucidates how biomarkers, genetics, and advances in neuroscience and neuroimaging have influenced drug development approaches, which will ultimately change the practice of psychiatry. The book charts the early years of drug discovery by chance observation, reviews the developments of the past 50 years of refined targeting of CNS drugs without the discovery of mechanistically new drugs, and looks to the discovery of mechanistically new drugs, the examination of new targets, genetics, and biomarkers.
|
| 588 |
|
|
|a Description based on online resource; title from digital title page (viewed on April 27, 2023).
|
| 650 |
|
0 |
|a Psychotropic drugs
|x Development.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
7 |
|a Drug development
|2 fast
|
| 700 |
1 |
|
|a Macaluso, Matthew,
|e editor.
|
| 700 |
1 |
|
|a Preskorn, Sheldon,
|e editor.
|
| 700 |
1 |
|
|a Shelton, Richard C.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t DRUG DEVELOPMENT IN PSYCHIATRY.
|d [Place of publication not identified] : SPRINGER INTERNATIONAL PU, 2023
|z 3031210530
|w (OCoLC)1347260744
|
| 830 |
|
0 |
|a Advances in neurobiology ;
|v 30.
|
| 856 |
4 |
0 |
|u https://holycross.idm.oclc.org/login?auth=cas&url=https://link.springer.com/10.1007/978-3-031-21054-9
|y Click for online access
|
| 903 |
|
|
|a SPRING-ALL2023
|
| 994 |
|
|
|a 92
|b HCD
|